Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection
暂无分享,去创建一个
V. Préat | G. Bastiat | K. Vanvarenberg | F. Danhier | B. Ucakar | B. Gallez | C. Bastiancich | J. Bianco | N. Joudiou | F. Lagarce | B Gallez | V Préat | F Danhier | B Ucakar | C Bastiancich | J Bianco | K Vanvarenberg | N Joudiou | G Bastiat | F Lagarce
[1] J. Abrams,et al. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. , 2012, Neuro-oncology.
[2] Qiang Zhang,et al. Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[3] B. L. Rodriguez,et al. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. , 2012, International journal of pharmaceutics.
[4] E. Holland,et al. Glioblastoma multiforme: the terminator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[5] Fred H. Hochberg,et al. Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.
[6] Alexander Jesacher,et al. A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[7] J. Benoit,et al. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. , 2015, International journal of pharmaceutics.
[8] J. Dichgans,et al. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. , 1999, European journal of pharmacology.
[9] Richard Assaker,et al. Local and Sustained Delivery of 5-Fluorouracil from Biodegradable Microspheres for the Radiosensitization of Malignant Glioma: A Randomized Phase II Trial , 2005, Neurosurgery.
[10] M. Grinstaff,et al. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[11] A. Mangraviti,et al. Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[12] Akio Asai,et al. Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging , 2010, Brain Tumor Pathology.
[13] C. Miller,et al. Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model. , 2016, Neuro-oncology.
[14] V. Préat,et al. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[15] M. Mizuno,et al. [Gene therapy for malignant glioma]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[16] M Brada,et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] N. Agarwal,et al. Optimal Timing of Whole-Brain Radiation Therapy Following Craniotomy for Cerebral Malignancies. , 2015, World neurosurgery.
[18] P. Brennan,et al. Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. , 2003, Clinical Infectious Diseases.
[19] M. Shiroishi,et al. Multimodal magnetic resonance imaging evaluation of primary brain tumors. , 2014, Seminars in oncology.
[20] O. Krizanova,et al. Athymic nude mice as an experimental model for cancer treatment. , 2016, Physiological research.
[21] F. Danhier,et al. Novel model of orthotopic U-87 MG glioblastoma resection in athymic nude mice , 2017, Journal of Neuroscience Methods.
[22] B. Rini,et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.
[23] C. Palazzo,et al. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[24] A. Tesnière,et al. Contribution du système immunitaire à l’efficacité des chimiothérapies anticancéreuses , 2008 .
[25] M. Chamberlain,et al. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. , 2012, Biochimica et biophysica acta.
[26] J. Benoit,et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats , 2006, Molecular Cancer Therapeutics.
[27] V. Préat,et al. On glioblastoma and the search for a cure: where do we stand? , 2017, Cellular and Molecular Life Sciences.
[28] H. Friedman,et al. Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas , 2007, Therapeutics and clinical risk management.
[29] Yong Yang,et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. , 2009, Cancer letters.
[30] J. Benoit,et al. A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers , 2002, Pharmaceutical Research.
[31] Z. Ram,et al. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.
[32] D. Schuppan,et al. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy. , 2016, Nanomedicine.
[33] J. Benoit,et al. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. , 2016, Biomaterials.
[34] J. Benoit,et al. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. , 2010, Biomaterials.
[35] C. Cass,et al. Inhibition of nucleoside transporters by tyrosine kinase inhibitors and its effects on chemotherapy efficacy , 2014 .
[36] P. Couvreur,et al. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. , 2016, Biomaterials.
[37] Li Di,et al. Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.
[38] V. Préat,et al. Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[39] J. Prehn,et al. Advances in immunotherapy for the treatment of glioblastoma , 2016, Journal of Neuro-Oncology.
[40] J. Biswas,et al. Recurrent Glioblastoma: Where we stand , 2015, South Asian Journal of Cancer.
[41] Manfred Westphal,et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.
[42] K. Hynynen,et al. Focused ultrasound-mediated drug delivery through the blood–brain barrier , 2015, Expert review of neurotherapeutics.
[43] J. Benoit,et al. An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure. , 2014, Soft matter.
[44] W. Hickey,et al. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model , 2011, ASN neuro.
[45] R. Lonser,et al. Surgery for glioblastoma multiforme: striking a balance. , 2011, World neurosurgery.
[46] N M F S A Cerqueira,et al. Gemcitabine: a critical nucleoside for cancer therapy. , 2012, Current medicinal chemistry.
[47] C. R. Crawford,et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.
[48] G. Faccani,et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies , 2010, Cell biochemistry and function.
[49] K. Kondo,et al. Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[50] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[51] V. Préat,et al. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[52] Erwin G. Van Meir,et al. Overcoming therapeutic resistance in glioblastoma: the way forward. , 2017, The Journal of clinical investigation.
[53] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[54] M. Mahoney,et al. Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: an analysis of the glial response across space and time. , 2010, Journal of biomedical materials research. Part A.
[55] T. Wurdinger,et al. Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. , 2014, Biochimica et biophysica acta.
[56] A. Saneja,et al. Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[57] Steve Y. Cho,et al. In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] J. Benoit,et al. The brain tissue response to biodegradable poly(methylidene malonate 2.1.2)-based microspheres in the rat. , 2006, Biomaterials.
[59] Karl Schaller,et al. Long-term survival of patients with glioblastoma multiforme (GBM) , 2013, Journal of Clinical Neuroscience.
[60] B. Greene,et al. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms , 2005, Cancer Chemotherapy and Pharmacology.
[61] T. Dwight,et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma , 2016, Scientific Reports.